We calculated the impact of 2,837 compounds on the CA20 transcriptomic levels in human cancer cell lines (S14 Table) and identified some whose activity drove CA20 up-regulation (putative CA promoters; S15 Fig), such as VEGFR2-kinase-inhibitor-IV, dienestrol (oestrogen receptor agonist) and sulforaphane (anticancer agent in clinical trials for Bladder, Breast, Lung and Prostate cancers; https://clinicaltrials.gov/ct2/results?cond=sulforaphane&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=). This evidence concerns the gene KDR and Familial prostate cancer.